RVTY · Revvity, Inc.

Revvity delivered revenue growth of 7.0% to $711.1 million in Q1 FY2026 from $664.8 million prior year, driven by underlying business momentum that expanded topline despite calendar distortions from an extra fiscal week. This topline strength flowed through to gross profit of $387.7 million, up 3.2% from $375.5 million, maintaining a solid gross margin of 54.5%. The increase reflects operational execution amid a dynamic market environment for life sciences and diagnostics solutions.

Operating income rose 5.1% to $75.9 million from $72.2 million, achieving an operating margin of 10.7%, as productivity initiatives and cost containment offset headwinds. Management notes segment operating margins faced pressure, with declines attributed to product mix shifts—favoring lower-margin products—changes in foreign exchange rates, increased tariffs, and the extra fiscal week's impact. These factors explain the moderated gross profit growth relative to revenue, highlighting the importance of mix management and FX hedging in preserving profitability.

Net income of $40.7 million represented a 3.6% decline from $42.2 million, yet diluted EPS advanced 2.9% to $0.36 from $0.35. This divergence stems from share repurchases that reduced outstanding shares, demonstrating capital allocation discipline to enhance per-share value even as absolute earnings faced pressures. The uptick in research and development expenses, driven by investments in new product development and elevated labor costs from the extra week, underscores strategic focus on innovation to fuel future growth.

Overall, Q1 results reflect resilient revenue growth and cash flow amid profitability challenges from external and mix-related factors. Management's emphasis on new product investments and cost discipline positions Revvity to navigate these dynamics while pursuing long-term value creation for shareholders.